Mirum Pharmaceuticals, Inc. (MIRM) Stock Overview
Explore Mirum Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Mirum Pharmaceuticals, Inc. (MIRM)
Key Financials
Key Financials
Market Cap
6.2B
P/E Ratio
-6.21
EPS (TTM)
$-14.55
ROE
-7.34%
MIRM Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Mirum Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of MIRM on the NASDAQ shows an RSI of 62.01, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $113.06 for the NASDAQ listing.
Key metrics behind Mirum Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -6.21 and a market capitalization of 6.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of MIRM on the NASDAQ.